Diagnosis  ||| S:0 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
therapy  ||| S:14 E:22 ||| NN
of  ||| S:22 E:25 ||| IN
atherosclerosis  ||| S:25 E:41 ||| NN
through  ||| S:41 E:49 ||| IN
molecular  ||| S:49 E:59 ||| JJ
biological  ||| S:59 E:70 ||| JJ
approaches  ||| S:70 E:81 ||| NNS
possibility  ||| S:81 E:93 ||| NN
of  ||| S:93 E:96 ||| IN
HDL-targeting  ||| S:96 E:110 ||| JJ
therapy  ||| S:110 E:118 ||| NN
by  ||| S:118 E:121 ||| IN
manipulation  ||| S:121 E:134 ||| NN
of  ||| S:134 E:137 ||| IN
micro  ||| S:137 E:143 ||| JJ
RNA-33  ||| S:143 E:150 ||| NNP
Elevated  ||| S:150 E:159 ||| NNP
levels  ||| S:159 E:166 ||| NNS
of  ||| S:166 E:169 ||| IN
low-density  ||| S:169 E:181 ||| NN
lipoprotein  ||| S:181 E:193 ||| NN
cholesterol  ||| S:193 E:205 ||| NN
( ||| S:205 E:206 ||| -LRB-
LDL-C ||| S:206 E:211 ||| NNP
)  ||| S:211 E:213 ||| -RRB-
increase  ||| S:213 E:222 ||| VB
the  ||| S:222 E:226 ||| DT
risk  ||| S:226 E:231 ||| NN
of  ||| S:231 E:234 ||| IN
coronary  ||| S:234 E:243 ||| JJ
heart  ||| S:243 E:249 ||| NN
disease  ||| S:249 E:257 ||| NN
( ||| S:257 E:258 ||| -LRB-
CHD ||| S:258 E:261 ||| NNP
) ||| S:261 E:262 ||| -RRB-
,  ||| S:262 E:264 ||| ,
and  ||| S:264 E:268 ||| CC
statin  ||| S:268 E:275 ||| JJ
therapy  ||| S:275 E:283 ||| NN
to  ||| S:283 E:286 ||| TO
decrease  ||| S:286 E:295 ||| VB
LDL-C  ||| S:295 E:301 ||| JJ
significantly  ||| S:301 E:315 ||| RB
reduces  ||| S:315 E:323 ||| VBZ
the  ||| S:323 E:327 ||| DT
risk  ||| S:327 E:332 ||| NN
of  ||| S:332 E:335 ||| IN
cardiovascular  ||| S:335 E:350 ||| JJ
events ||| S:350 E:356 ||| NNS
.  ||| S:356 E:358 ||| .
Despite  ||| S:358 E:366 ||| IN
the  ||| S:366 E:370 ||| DT
effectiveness  ||| S:370 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
statin  ||| S:387 E:394 ||| JJ
therapy ||| S:394 E:401 ||| NN
,  ||| S:401 E:403 ||| ,
there  ||| S:403 E:409 ||| EX
remains  ||| S:409 E:417 ||| VBZ
a  ||| S:417 E:419 ||| DT
significant  ||| S:419 E:431 ||| JJ
residual  ||| S:431 E:440 ||| JJ
cardiovascular  ||| S:440 E:455 ||| JJ
risk ||| S:455 E:459 ||| NN
.  ||| S:459 E:461 ||| .
A  ||| S:461 E:463 ||| DT
low  ||| S:463 E:467 ||| JJ
plasma  ||| S:467 E:474 ||| JJ
concentration  ||| S:474 E:488 ||| NN
of  ||| S:488 E:491 ||| IN
high-density  ||| S:491 E:504 ||| JJ
lipoprotein  ||| S:504 E:516 ||| JJ
cholesterol  ||| S:516 E:528 ||| NN
( ||| S:528 E:529 ||| -LRB-
HDL-C ||| S:529 E:534 ||| NNP
)  ||| S:534 E:536 ||| -RRB-
is  ||| S:536 E:539 ||| VBZ
associated  ||| S:539 E:550 ||| VBN
with  ||| S:550 E:555 ||| IN
an  ||| S:555 E:558 ||| DT
increased  ||| S:558 E:568 ||| JJ
risk  ||| S:568 E:573 ||| NN
of  ||| S:573 E:576 ||| IN
CHD ||| S:576 E:579 ||| NNP
.  ||| S:579 E:581 ||| .
However ||| S:581 E:588 ||| RB
,  ||| S:588 E:590 ||| ,
recent  ||| S:590 E:597 ||| JJ
clinical  ||| S:597 E:606 ||| JJ
trials  ||| S:606 E:613 ||| NNS
aimed  ||| S:613 E:619 ||| VBN
at  ||| S:619 E:622 ||| IN
reducing  ||| S:622 E:631 ||| VBG
the  ||| S:631 E:635 ||| DT
CHD  ||| S:635 E:639 ||| NNP
risk  ||| S:639 E:644 ||| NN
by  ||| S:644 E:647 ||| IN
raising  ||| S:647 E:655 ||| VBG
HDL-C  ||| S:655 E:661 ||| JJ
levels  ||| S:661 E:668 ||| NNS
have  ||| S:668 E:673 ||| VBP
not  ||| S:673 E:677 ||| RB
shown  ||| S:677 E:683 ||| VBN
satisfactory  ||| S:683 E:696 ||| JJ
results ||| S:696 E:703 ||| NNS
,  ||| S:703 E:705 ||| ,
and  ||| S:705 E:709 ||| CC
it  ||| S:709 E:712 ||| PRP
is  ||| S:712 E:715 ||| VBZ
becoming  ||| S:715 E:724 ||| VBG
evident  ||| S:724 E:732 ||| JJ
that  ||| S:732 E:737 ||| IN
a  ||| S:737 E:739 ||| DT
functional  ||| S:739 E:750 ||| JJ
HDL-C  ||| S:750 E:756 ||| NN
is  ||| S:756 E:759 ||| VBZ
a  ||| S:759 E:761 ||| DT
more  ||| S:761 E:766 ||| RBR
desirable  ||| S:766 E:776 ||| JJ
target  ||| S:776 E:783 ||| NN
than  ||| S:783 E:788 ||| IN
simply  ||| S:788 E:795 ||| RB
elevating  ||| S:795 E:805 ||| VB
its  ||| S:805 E:809 ||| PRP$
level ||| S:809 E:814 ||| NN
.  ||| S:814 E:816 ||| .
This  ||| S:816 E:821 ||| DT
review  ||| S:821 E:828 ||| NN
summarizes  ||| S:828 E:839 ||| VBD
the  ||| S:839 E:843 ||| DT
function  ||| S:843 E:852 ||| NN
of  ||| S:852 E:855 ||| IN
HDL-C  ||| S:855 E:861 ||| JJ
in  ||| S:861 E:864 ||| IN
reverse  ||| S:864 E:872 ||| JJ
cholesterol  ||| S:872 E:884 ||| NN
transfer  ||| S:884 E:893 ||| NN
from  ||| S:893 E:898 ||| IN
peripheral  ||| S:898 E:909 ||| JJ
tissue  ||| S:909 E:916 ||| NN
and  ||| S:916 E:920 ||| CC
discusses  ||| S:920 E:930 ||| VBG
the  ||| S:930 E:934 ||| DT
latest  ||| S:934 E:941 ||| JJS
HDL-targeting  ||| S:941 E:955 ||| JJ
therapeutic  ||| S:955 E:967 ||| JJ
strategies  ||| S:967 E:978 ||| NNS
including  ||| S:978 E:988 ||| VBG
the  ||| S:988 E:992 ||| DT
manipulation  ||| S:992 E:1005 ||| NN
of  ||| S:1005 E:1008 ||| IN
microRNAs ||| S:1008 E:1017 ||| JJ
.  ||| S:1017 E:1019 ||| .
